lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-09 and is reviewed periodically as new material appears.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
19 December – UK government minister Tulip Siddiq is named in an investigation into allegations her family embezzled up to £3.9bn from infrastructure projects in Bangladesh. Jane Meagher is voted to replace Cammy Day as leader of Edinburgh City Council, and will lead a Labour minority administration. The Stormont Executive agrees to release its draft budget for the 2025/26 financial year for public consultation, with much of the £19bn budget earmarked for health and education. 20 December – Labour appoint 30 new peers, including former Downing Street chief of staff Sue Gray, while the Conservatives appoint six, including former deputy prime minister Therese Coffey. Peter Mandelson is appointed as the next UK ambassador to the United States. 21 December – US president-elect Donald Trump appoints British TV executive Mark Burnett as the inaugural United States Special Envoy to the United Kingdom. 23 December – Sir Keir Starmer holds talks with Ukrainian president Volodymyr Zelenskyy during which they agreed on the "importance of refining" the UK's training of Ukrainian forces to "bolster" Ukraine's defence. Conservative leader Kemi Badenoch says there is no "quick fix" for the Conservative Party following its election loss, and that she will not be rushed into making policy announcements. 26 December – The Reform UK website, and its leader, Nigel Farage, have said that party membership has passed the 131,680 declared by the Conservatives.
AOD9604 is an orally active, lipolytic 16-amino acid peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the N-terminal end. Initial human trials showed that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production. However, later studies failed to demonstrate a sufficient lipolytic effect. Its development was terminated in 2007. Despite its limited efficacy, AOD9604 is still banned in athletes and tested for in competition. AOD9604 appears to enhance lipolysis in mice by upregulating beta-3 adrenergic receptors. Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604. In a 12 week randomised clinical trial, subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving placebo. Development of AOD9604 was halted following poor efficacy in a later 24 week trial.
Believing that Gary, the Nosferatu chief, has stolen the sarcophagus, the fledgling is sent to Hollywood to find him; after locating a captured Nosferatu for Gary, he reveals that the Giovanni vampire clan stole the sarcophagus. The fledgling infiltrates the Giovanni mansion and finds the sarcophagus guarded by the Kuei-Jin, who claim their leader, Ming-Xiao, has allied with LaCroix. The locked sarcophagus is returned to LaCroix's tower, and Beckett, a vampire scholar, tells the fledgling that the only person who can open it has been abducted by Bach to lure LaCroix. The fledgling kills Bach and learns that the sarcophagus's key has been stolen. The fledgling returns to LaCroix, learning that the Sabbat tried to steal the sarcophagus to destroy it and prevent Gehenna, then kills the Sabbat leader to disperse his followers. The fledgling is met by Ming-Xiao, who offers an alliance. Ming-Xiao reveals that she has the key, and LaCroix killed Grout to prevent his powerful insight from unveiling LaCroix's plans; Ming-Xiao disguised herself as Nines at the mansion to frame him. Denying Ming-Xiao's claims, LaCroix rescinds the blood hunt on Nines and entrusts the fledgling with recruiting the anarchs to punish the Kuei-Jin for murdering Grout. The fledgling finds Nines hiding in Griffith Park, and they are then attacked by a werewolf, and Nines is badly injured. The fledgling escapes with Jack, who reveals that LaCroix has issued an execution order on the fledgling for framing Nines on Ming-Xiao's orders.
Bexagliflozin was approved in the United States under the brand name Brenzavvy in January 2023. Canagliflozin is the first SGLT2 inhibitor to be approved for use in the United States. It was approved in March 2013, under the brand name Invokana, and it was also marketed throughout the European Union under the same name. Dapagliflozin (brand name Forxiga) was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. It was approved for use in the United States under the brand name Farxiga in January 2014. Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. Enavogliflozin, developed by GC Pharma and Daewoong Pharmaceutical. Approved for clinical use in South Korea and Ecuador. Ertugliflozin was approved in the United States under the brand name Steglatro in December 2017. Henagliflozin, selective SGLT2 inhibitor. Approved in China in 2022. Ipragliflozin, produced by the Japanese company Astellas Pharma Inc. under the brand name Suglat, approved in Japan in January 2014. Luseogliflozin, developed by Taisho Pharmaceutical, was approved in Japan in March 2014, under the brand name Lusefi. Remogliflozin etabonate was commercially launched first in India by Glenmark in May 2019.
The 1st Gold Corps was renamed to the China Geological Survey Harbin Natural Resources Comprehensive Research Center. The 1st Gold Detachment was renamed to the China Geological Survey Mudanjiang Natural Resources Comprehensive Research Center. The 2nd Gold Detachment was renamed to the China Geological Survey Hohhot Natural Resources Comprehensive Research Center The 5th Gold Detachment was renamed to the China Geological Survey Xi'an Mineral Resources Research Center. The 6th Gold Detachment was renamed to the China Geological Survey Xining Natural Resources Comprehensive Research Center. The 8th Gold Detachment was renamed to the China Geological Survey Ürümqi Natural Resources Comprehensive Research Center. The 9th Gold Detachment was renamed to the China Geological Survey Haikou Marine Geology Research Center The 10th Gold Detachment was renamed to the China Geological Survey Kunming Natural Resources Comprehensive Research Center. The 11th Gold Detachment was renamed to the China Geological Survey Changsha Natural Resources Comprehensive Research Center. The Research Institute and Training Battalion were renamed to the China Geological Survey Geophysics Research Center in Langfang.
Sources: en.wikipedia.org
However, M2 dermal macrophages might also arrest the hair growth cycle at telogen. Further research is needed to determine the functional roles of M2 dermal macrophages. Although the contribution of M1 and M2 dermal macrophages to hair regeneration is still unclear, the contribution of the dermal macrophage population is still noticeable regardless of their phenotypes.
=== Later medieval works === The Fisher King is a character in Chrétien's Perceval (1180) which is the first of a series of stories and texts on the subject of Perceval and the Grail. In his work, Chrétien did not say how the quester was related to this Fisher King. In later romances it is made clear, in the end, that he is the uncle of the quester. According to Eugène Vinaver, Chretien's work features two Maimed Kings. Parzival was written in 1210 by Wolfram von Eschenbach, thirty years after Perceval. Although a different work, it is strikingly similar to Perceval. The story revolves around the Grail Quest and once again the main character is Perceval (as Parzival). As in Perceval, the story has its protagonist fail to ask the healing question, which results in him Questing for years. However, Parzival differs from Perceval in three major ways. Firstly, the Fisher King is no longer nameless and is called Anfortas. Secondly, Eschenbach thoroughly describes the nature of the wound; it is a punishment for wooing a woman who is not meant for him (every Grail keeper is to marry the woman the Grail determines for him), and it causes him immense pain. Lastly, Parzival comes back to cure the Fisher King. Parzival, unlike its predecessor Perceval, has a definitive ending. The quester is the son of Herzeloyde, who is the sister of Anfortas.
Countries have differing standards for grading honey. In the US, honey grading is performed voluntarily based upon USDA standards. USDA offers inspection and grading "as on-line (in-plant) or lot inspection...upon application, on a fee-for-service basis." Honey is graded based upon a number of factors, including water content, flavor and aroma, absence of defects, and clarity. Honey is also classified by color, though it is not a factor in the grading scale. The USDA honey grade scale is:
In the late 2000s, the Cherngs began implementing play areas, known as the Panda Express Play Places, which had been developed in the late 90's by their business partner, Reginald Schwaab. The Play Places were a major success, primarily on the East Coast of America, where the chain continued to succeed. Due to COVID and increased costs regarding upkeep, the play places were removed from the chain in August 2020.
== Research == There is little evidence that turkey tail mushroom extracts or PSK are useful for treating cancer or any medical condition. Polysaccharide-K, an extract of T. versicolor, is approved in Japan as an adjuvant therapy in cancer treatment.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.